Theravance Biopharma’s Phase 3 Failure Triggers Cost Cuts and Sale Exploration

Theravance Biopharma's ampreloxetine failed its Phase 3 CYPRESS study for nOH in MSA. Company winds down program, cuts costs ~60%, focuses on YUPELRi cash flow, and speeds up strategic alternatives review to maximize shareholder value.